[Edaily Reporter Park Jung-Soo ] Pangen Biotech Inc.(222110)announced on the 22nd that it has been awarded a research contract worth 2.74545 billion won from the National Institute of Health under the Korea Disease Control and Prevention Agency (KDCA) for the “Optimization and Evaluation of a Non-clinical Sample Production System for Antibodies to Treat Severe Fever with Thrombocytopenia Syndrome (SFTS).” The contract amount represents 20.46% of last year’s revenue, and the contract period runs through December 31, 2028.
Disclosure Plus
Pangen Biotech Inc. Wins 2.7 Billion Won Research Contract from the National Institute of Health
Economy
Corporation
IT·Science
Economy
Lee Jae-yong Attends ‘Sun Valley,’ a Gathering of Billionaires… Expanding His Global AI Footprint
SamsungElectronics Chairman Lee Jae-yong is expected to attend the Sun Valley Conference, widely regarded as a social gathering for global business leaders.According to foreign media and business circ…
Corporation
Hyundai Department Store Receives 'Top' Rating in SustainBest ESG Assessment
Hyundai Department Store ( HYUNDAIDEPARTMENTSTORECO.,LTD(069960)) announced on the 5th that it received the highest rating of “AA” in the first half of this year’s ESG evaluation conducted by SustainB…
IT·Science
FDE: OpenAI, SAP, and Microsoft Have Joined the Fray… The Rules for Corporate AI Adoption Are Changing
The way global companies adopt artificial intelligence (AI) is rapidly shifting toward a field-based engineering approach. As the ability to successfully integrate AI into actual business systems beco…
